Plasma microRNA-1207-5p as a Potential Biomarker for Diagnosis and Prognosis of Colorectal Cancer
- PMID: 32902212
- DOI: 10.7754/Clin.Lab.2020.191269
Plasma microRNA-1207-5p as a Potential Biomarker for Diagnosis and Prognosis of Colorectal Cancer
Abstract
Background: MicroRNA-1207-5p (miR-1207-5p) has been identified as a tumor suppressor in many types of cancer. In our previous research, we found that the expression of miR-1207-5p in cancer tissues and cell lines were both down-regulated, and miR-1207-5p may function as tumor suppressor in colorectal cancer (CRC). However, less research has been done with respect to the expression of plasma miR-1207-5p in CRC or colorectal adenoma (CRA). There was no research regarding the diagnostic ability nor on the prognostic value of plasma miR-1207-5p in CRC. We conducted a preliminary study on the plasma miRNA-1207-5p as a non-invasive biomarker in CRC.
Methods: Plasma miR-1207-5p expression was quantified by qRT-PCR from CRC patients (n = 64), CRA patients (n = 42), and normal controls (n = 36). The blood samples were collected after having been diagnosed by pathology but before surgical resection and radio-chemotherapy. The CRC patients were divided into low and high expression groups according to the mean expression level of plasma miR-1207-5p. The relation of expression levels of miR-1207-5p and overall survival were analyzed by Kaplan-Meier survival curves. The receiver operating characteristic (ROC) curves were generated to assess the diagnostic ability of plasma miR-1207-5p in CRC.
Results: The expression of plasma miR-1207-5p was obvious down-regulated both in CRC patients (mean ± SD: 0.1661 ± 0.0083) and CRA patients (mean ± SD: 0.2480 ± 0.0162) compared to normal controls. The lower the ex-pression of plasma miR-1207-5p, the stronger the association with advanced TNM stage and positive lymph node metastasis compared with the high expression group (p = 0.027, p = 0.033). The lower the expressions of plasma miR-1207-5p, the shorter the overall survival time for CRC patients (p = 0.0404). There was no significant difference in the relative expression of plasma miR-1207-5p between the preoperative group and postoperative group. ROC analysis showed that the diagnostic sensitivity and specificity were 95.31% and 94.44% (at a cutoff = 0.2990) for CRC patients, 90.48% and 80.56% (at a cutoff = 0.4060) for CRA patients, respectively. The AUC value was 0.9852 (95% CI = 0.9870 - 1.0003, p < 0.0001), and 0.9530 (95% CI = 0.9117 - 0.9944, p < 0.0001), respectively.
Conclusions: Significant down-regulation of plasma miR-1207-5p was correlated with poor survival and with strong diagnostic ability and may function as a potential biomarker for diagnosis and prognosis of colorectal cancer.
Similar articles
-
A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis.Gene. 2019 Mar 1;687:246-254. doi: 10.1016/j.gene.2018.11.055. Epub 2018 Nov 17. Gene. 2019. PMID: 30458288
-
Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer.World J Gastroenterol. 2014 Sep 14;20(34):12241-8. doi: 10.3748/wjg.v20.i34.12241. World J Gastroenterol. 2014. PMID: 25232258 Free PMC article.
-
The potential of plasma microRNAs as non-invasive biomarkers in patients with colorectal cancer in advanced tumor-node-metastasis stages.Eur Rev Med Pharmacol Sci. 2025 Feb;29(2):74-85. doi: 10.26355/eurrev_202502_37098. Eur Rev Med Pharmacol Sci. 2025. PMID: 40026138
-
Role of miR-21 in the diagnosis of colorectal cancer: Meta-analysis and bioinformatics.Pathol Res Pract. 2023 Aug;248:154670. doi: 10.1016/j.prp.2023.154670. Epub 2023 Jul 3. Pathol Res Pract. 2023. PMID: 37418993 Review.
-
The role of miRNAs in the pathogenesis, diagnosis, and treatment of colorectal cancer and colitis-associated cancer.Clin Exp Med. 2025 Mar 16;25(1):86. doi: 10.1007/s10238-025-01582-6. Clin Exp Med. 2025. PMID: 40091000 Free PMC article. Review.
Cited by
-
Impact of MICA 3'UTR allelic variability on miRNA binding prediction, a bioinformatic approach.Front Genet. 2023 Dec 7;14:1273296. doi: 10.3389/fgene.2023.1273296. eCollection 2023. Front Genet. 2023. PMID: 38146340 Free PMC article.
-
GUCA2A dysregulation as a promising biomarker for accurate diagnosis and prognosis of colorectal cancer.Clin Exp Med. 2024 Nov 1;24(1):251. doi: 10.1007/s10238-024-01512-y. Clin Exp Med. 2024. PMID: 39485546 Free PMC article.
-
Clinical significance of microRNA-1180-3p for colorectal cancer and effect of its alteration on cell function.Bioengineered. 2021 Dec;12(2):10491-10500. doi: 10.1080/21655979.2021.1997694. Bioengineered. 2021. PMID: 34723759 Free PMC article.
-
Plasma microRNA-192-5p can predict the response to neoadjuvant chemotherapy and prognosis in esophageal cancer.Cancer Sci. 2023 Apr;114(4):1686-1696. doi: 10.1111/cas.15703. Epub 2022 Dec 26. Cancer Sci. 2023. PMID: 36533956 Free PMC article.
-
BTEB2-Activated lncRNA TSPEAR-AS2 Drives GC Progression through Suppressing GJA1 Expression and Upregulating CLDN4 Expression.Mol Ther Nucleic Acids. 2020 Oct 22;22:1129-1141. doi: 10.1016/j.omtn.2020.10.022. eCollection 2020 Dec 4. Mol Ther Nucleic Acids. 2020. PMID: 33294297 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical